Indication intelligence, analysis and sector perception

REGENXBIO (RGNX) proposes a $175 M offering

August 8, 2018

RGNX closed down -$0.25 to $70.55 with an aftermarket downside of -$0.45 or -0.64% - SELL After reporting Q2 net income of $10.6 M or a profit of $0.30 per share; earnings, adjusted for non-recurring gains, were $0.15 per share.

bluebird bio (BLUE) prices 3.348 M share offering at $162.50

July 25, 2018

BLUE had closed down -$13.60 to $163.65after Monday's -$3.10 to $177.25 and is down another -$0.65 or -0.40%  – Maintaining SELL; The estimated proceeds are approximated at $550 M aith an overalottment of 507,692 shares Goldman Sachs & Co. LLC, BofA Merrill Lynch, J.P. Morgan Securities LLC and Cowen are acting as joint book-running managers and Wells Fargo Securities is acting as co-manager of the proposed offering. 

CRSPR stocks stay in the tank in another session…

July 24, 2018

CRSP (-$6.33 or -11.05%), EDIT (-$2.89 or -8.17%) and NTLA (-$2.89 or -8.17%) at Tuesday’s mid-day Yet another “shuffle” to the downside… as I had stated, it ain’t over … falling precipitously in the day’s range!

Roll Call

The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.